Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobeglitazone Added to Metformin in Type 2 Diabetes
NCT01106131Phase 3Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lobeglitazone in type 2 diabetes mellitus (T2DM), sponsored by Chong Kun Dang Holdings. Started May 2010; status: completed.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01106131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01106131.